Peritoneovenous shunting for nongynecologic malignant ascites Journal Article


Authors: Bieligk, S. C.; Calvo, B. F.; Coit, D. G.
Article Title: Peritoneovenous shunting for nongynecologic malignant ascites
Abstract: BACKGROUND. The development of malignant ascites has been associated with a poor prognosis. Previous reports have documented high morbidity rates associated with placement of palliative peritoneovenous shunts (PVS). Most study series have included gynecologic malignancies in their analysis, and wide variations in survival time have been reported. Reported data from nongynecologic malignancies and identification of preoperative factors associated with improved outcome were the concerns of the current study, which attempted to identify patients with malignant ascites who might have benefitted from PVS. METHODS. A retrospective chart review was performed and data including age, gender, weight, preoperative laboratory values, cytology on peritoneal fluid aspirates, and complications within 30 days of the operative procedure were obtained and recorded. Discharge date and follow-up status were obtained for all patients. Statistical analysis was done for categorical values by comparing survival times from date of procedure with follow-up times using the log rank test. Significance for numeric values was determined with Cox regression analysis. Multivariate analysis using Cox regression was performed for those values found to be significant on univariate analysis. RESULTS. Fifty- five patients who had undergone PVS from 1980-1996 for ascites on the Gastric and Mixed Tumor service at the Memorial Sloan-Kettering Cancer Center were identified. Two patients with benign disease and two patients with ovarian malignancies were excluded. The remaining 51 patients underwent placement of 53 PVSs for palliation. Median survival time for the entire group was 52 days. Univariate analysis identified preoperative blood urea nitrogen (BUN), creatinine (Cr), BUN to Cr ratio, and diagnosis as significant factors. Preoperative BUN emerged as an independent predictor of survival by multivariate analysis, and those patients who had a BUN value of ≤ 17 demonstrated a survival advantage over those with a BUN of > 17. The assessable palliation factors were hospital discharge (80% of patients) and weight loss after shunting (68% of patients lost > 1 kg). Ninety-six percent of patients (24 of 25) with a preoperative BUN of ≤ 17 were discharged. CONCLUSIONS. The development of nongynecologic malignant ascites is an end stage event for most patients. The placement of PVS for those patients with nongastrointestinal tumor etiologies, a BUN of < 17, a Cr of ≤ 1.1, and a BUN to Cr ratio of < 19 yielded the best results. In the current study, palliation was difficult to assess accurately, although most patients were discharged or lost > 1kg of weight after shunting. © 2001 American Cancer Society.
Keywords: adult; cancer survival; treatment outcome; aged; aged, 80 and over; middle aged; survival rate; retrospective studies; major clinical study; ascites; neoplasms; treatment indication; palliative care; breast cancer; creatinine; urea nitrogen blood level; mesothelioma; lung carcinoma; urogenital tract tumor; multivariate analysis; shunting; paracentesis; diuresis; peritoneal cytology; blood urea nitrogen; humans; prognosis; human; male; female; priority journal; article; malignant ascites; peritoneovenous shunt
Journal Title: Cancer
Volume: 91
Issue: 7
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2001-04-01
Start Page: 1247
End Page: 1255
Language: English
DOI: 10.1002/1097-0142(20010401)91:7<1247::aid-cncr1125>3.0.co;2-w
PUBMED: 11283923
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 21 May 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Daniel Coit
    422 Coit